<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19920">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01790711</url>
  </required_header>
  <id_info>
    <org_study_id>FMT-CN-121025</org_study_id>
    <nct_id>NCT01790711</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplantation on Type 2 Diabetes Mellitus</brief_title>
  <official_title>The Efficiency of Fecal Microbiota Transplantation on Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Second Hospital of Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Second Hospital of Nanjing Medical University</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The gut microbiota is considered to constitute a &quot;microbial organ&quot; which has pivotal roles
      in the body's metabolism. Evidence from animal and human studies strongly support the link
      between intestinal bacteria and type 2 diabetes mellitus. The present clinical trial aims to
      re-establish a gut functionality state of intestinal flora through fecal microbiota
      transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We established a standard bacteria isolation from donated fresh stool in lab.Then the
      bacteria is transplanted to mid-gut (at least below the second part of duodenum ) through
      regular gastroscope. Participants in this study will be randomly assigned to receive fecal
      microbiota transplantation only once or traditional therapy, and accept follow-up for at
      least one year. Blood tests,OGTT and magnetic resonance spectroscopy will be used to assess
      participants at study start and at study completion.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The Efficiency of FMT on T2DM</measure>
    <time_frame>Up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Confirmed by the tests of blood glucose level, OGTT, HACb1 and C-peptide.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Durability</measure>
    <time_frame>Up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure the durability of the therapy effects.Based on the tests of blood glucose level, HACb1 and C-peptide. BMI also will be observed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Efficiency</condition>
  <condition>Methodology</condition>
  <arm_group>
    <arm_group_label>FMT by endoscopy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once, fresh or frozen bacteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FMT through mid-gut</intervention_name>
    <arm_group_label>FMT by endoscopy</arm_group_label>
    <other_name>FMT through mid-gut by gastroscope</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Type 2 diabetes mellitus

        Exclusion Criteria:

        With any cause of liver disease other than fatty liver Known or suspected cirrhosis
        Inability or unwillingness to undergo OGTT and magnetic resonance procedures Requirement
        of long-term antibiotic therapy Pregnancy, breast-feeding, or plans to become pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed</url>
    <description>Fecal microbiota transplantation</description>
  </link>
  <reference>
    <citation>Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012 Oct;143(4):913-6.e7. doi: 10.1053/j.gastro.2012.06.031. Epub 2012 Jun 20. Erratum in: Gastroenterology. 2013 Jan;144(1):250.</citation>
    <PMID>22728514</PMID>
  </reference>
  <reference>
    <citation>Koren O, Goodrich JK, Cullender TC, Spor A, Laitinen K, Bäckhed HK, Gonzalez A, Werner JJ, Angenent LT, Knight R, Bäckhed F, Isolauri E, Salminen S, Ley RE. Host remodeling of the gut microbiome and metabolic changes during pregnancy. Cell. 2012 Aug 3;150(3):470-80. doi: 10.1016/j.cell.2012.07.008.</citation>
    <PMID>22863002</PMID>
  </reference>
  <reference>
    <citation>Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol. 2011 Dec 20;9(2):88-96. doi: 10.1038/nrgastro.2011.244. Review.</citation>
    <PMID>22183182</PMID>
  </reference>
  <reference>
    <citation>Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol. 2013 Jan;29(1):79-84. doi: 10.1097/MOG.0b013e32835a4b3e.</citation>
    <PMID>23041678</PMID>
  </reference>
  <reference>
    <citation>Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol. 2012 Nov;107(11):1755; author reply p.1755-6. doi: 10.1038/ajg.2012.251.</citation>
    <PMID>23160295</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 15, 2013</lastchanged_date>
  <firstreceived_date>February 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Second Hospital of Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Faming Zhang</investigator_full_name>
    <investigator_title>Vice chief, medical center for digestive diseases</investigator_title>
  </responsible_party>
  <keyword>Gut bacteria</keyword>
  <keyword>Bacteria</keyword>
  <keyword>Fecal transplant</keyword>
  <keyword>Bacteriotherapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
